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Background: The most important prognostic factor in the ovarian cancer is optimal cytoreduction. The neoadjuvant
chemotherapy, an only optional method of treatment in this case and is still the subject of debate. The object of this
study was to evaluate the usefulness of markers: CA 125, HE4, YKL-40 and bcl-2 as well as cathepsin L in predicting
optimal cytoreduction and response to chemotherapy.
Methods: Sera were secured preoperatively. The division into groups was performed retrospectively depending on the
method of treatment (surgery vs neoadjuvant chemotherapy) as well as on response to chemotherapy (sensitive vs
resistant vs refractory). Comparisons were made between groups, and the diagnostic usefulness of tested proteins was
examined.
Results: We found that statistically significant differences between primary operated patients and patients undergoing
neoadjuvant chemotherapy were applicable only to the tumour markers (CA125 1206.79 vs 2432.38, p = 0.000191; HE4
78.87 vs 602.45, p = 0.000004; YKL-40 108.13 vs 203.96, p = 0.003991). Cathepsin-L and Bcl-2 were statistically
insignificant. The cut-off point values were determined for the CA 125 (345 mIU/ml), HE4 (218.43 pmol/L) and YKL-40
(140.9 ng/ml). The sensitivity, specificity, PPV and NPV were as follows: CA125 (83.3%; 75%; 80.6%; 78.3%), HE4 (86.6%;
91.3%; 92.9%; 84%) and YKL-40 (75%; 83.3%; 84%; 74.1%).
Conclusion: Among the tested proteins the HE4 marker appears to be helpful in forecasting of optimal cytoreduction
and possibly also of the prediction of response to platinum analogues used in first-line treatment of ovarian cancer.
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Although the SEER report (National Cancer Institute
Surveillance, Epidemiology, and End Results) shows a
significant improvement in 5-year survival rate of pa-
tients with advanced ovarian cancer after the introduc-
tion of chemotherapy with paclitaxel and platinum
analogues, the 10-year survival rate is still very low and
is less than 10%. The generally accepted standard for
ovarian cancer treatment at present consists in maximally
cytoreductive surgery followed by cytotoxic adjuvant
chemotherapy based on platinum and taxane compounds* Correspondence: anitagl@poczta.onet.pl
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article, unless otherwise stated.[1,2]. The main prognostic factor for patients with ad-
vanced ovarian cancer is maximal cytoreductive surgery,
the maximum reduction in tumor size [3]. Unfortunately,
not in all the patients with ovarian cancer it is possible
to perform the primary, maximally cytoreductive onco-
logical surgery without further exposing them to severe
post-operative complications, while not meeting the re-
quirement of no residual disease. Performing surgical pro-
cedures on primarily very advanced ovarian cancers may
require the large intestine resection, resection of the dia-
phragm, spleen, partial liver resection. If at such a wide
surgery the effect of complete cytoreduction is not
achieved, the surgery being only a suboptimal procedure,
the patient will not benefit from such a treatment, and the
expected postoperative complications will delay the startCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this






FIGO I and II 17 30.4
FIGO III and IV 39 60.6
Grade 1 10 17.9
Grade 2 16 28.6
Grade 3 30 53.5
Serous type 45 80.4
Mucinous type 3 5.4
Endometriod type 3 5.4
Clear cell type 5 8.8
Primary optimal cytoreduction surgery 25 44.6
Neoadjuvant chemotherapy 31 55.4
Platinum sensitive 30 53.6
Platinum resistant 17 30.3
Platinum refractory 9 16.1
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prognosis [4-6]. For about two decades the neoadjuvant
chemotherapy has been successfully used in gynecologic
oncology, in order to reduce the tumour mass and enable
the optimal cytoreductive surgery after several courses of
therapy [7]. The neoadjuvant chemotherapy is still of
interest to physicians and scientists involved in the treat-
ment of ovarian cancer. There are reports describing even
a better prognosis for patients following the neoadjuvant
chemotherapy [8], however the opinions are prevailing
that it is a therapy by which similar long-term effects
of treatment are achieved, as compared with the pri-
mary surgery [9]. It seems that the main problem is to
isolate a group of women with ovarian cancer, which
shall most benefit from treatment with neoadjuvant
chemotherapy followed by interval debulking surgery.
In the recent several years there have been scientific
reports, aiming at identifying predictive factors for this
group of patients [10,11]. These are research works
both on imaging methods, investigating the biology of
neoplastic tumours alone, as well as analysis of serous
tumour markers [12-15].
The aim of the study was preliminary analysis if pre-
operative serum levels of CA 125, HE 4, YKL-40, bcl-2
and cathepsin-L could be helpful predictors for optimal
cytoreductive surgery and response to platinum therapy
in patients with malignant epithelial ovarian tumours.
Materials and methods
To the study group the 70 consecutive patients with
ovarian cancer were primarily enrolled. After analyzing
the criteria for their inclusion, the final analysis was car-
ried out on 56 patients diagnosed with ovarian cancer
treated at the Department of Gynecological Surgery and
Gynecological Oncology of Adults and Adolescents,
Pomeranian Medical University.
The following criteria were adopted for inclusion:
○ diagnosed malignant epithelial ovarian cancer
○ having a full course of treatment with the first-line
chemotherapy
○ a minimum follow-up six months after the last course
of chemotherapy
○ expressing informed consent to the study
The exact characteristics of the patients are shown in
Table 1.
The study was of a retrospective character. Patients
reporting at the clinic, who were suspected of ovarian
cancer, signed their informed consents to the study and
then had their blood samples taken on the day prior to
the planned surgery. Serum was centrifuged and then it
was frozen at temperature – 70°C until performing the
tests HE4, YKL-40, cathepsin -L and bcl-2. The testingof each patient with CA 125 marker was performed in
the preoperative period on date of blood sample taking.
Eligibility for surgery was based on clinical examin-
ation, CT or ultrasound imaging examinations. Patients
who were suspected of very advanced neoplastic process
and the likely inability to make a complete cytoreductive
surgery were assessed as eligible for diagnostic laparos-
copy, and in the absence of suspicion of high progres-
sion - to laparotomy. The necessity of conversion from
laparoscopy to laparotomy due to the positive assess-
ment of the complete resection ability of the neoplastic
lesions occurred in 9 cases. On the other hand, as many
as eight cases of laparotomy were of explorative charac-
ter because the cytoreductive surgery failed to be per-
formed. Finally, optimal debulking was achieved in 25
patients, and 31 were qualified as eligible for the neoad-
juvant chemotherapy.
The patients after primary cytoreduction received six cy-
cles of adjuvant chemotherapy with paclitaxel-carboplatin.
Patients after primary investigative diagnostic surgery
(laparoscopy or laparotomy) received 3–4 courses of neo-
adjuvant chemotherapy and then secondary cytoreductive
surgery was performed on them, followed by subsequent
courses of chemotherapy with paclitaxel-carboplatin.
The patients’ sensitivity to platinum analogues was
evaluated according to the following criteria:
○ the platinum sensitive patients, if the disease-free time
period was longer than 6 months after the end of the
first-line chemotherapy
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period was shorter than 6 months after the end of the
first-line chemotherapy
○ the platinum refractory patients, if disease progression
occurred during the first-line chemotherapy
Progression of the disease was diagnosed on the basis
of the value of CA 125 and CT results according to the
RECIST criteria [16].
Due to the nature of the study, which focused on se-
lected prognostic factors in women with ovarian cancer
it was not possible to create a control group of volun-
teers with no history of ovarian cancer.Table 2 Preoperative markers, bcl-2 and cathepsin–L serum








Median 190.7 600 p = 0.000191Markers analysis
All tumour markers were performed in the Laboratory of
Hormones and Tumour Markers at the Department of
Gynecological Surgery and Gynecological Oncology of
Adults and Adolescents, Pomeranian Medical University.
CA 125 levels were determined using CA125 immuno-
assay (EIA) system according to instructions from Abbott,
(IMX, Abbott CA 125, Abbott Laboratories, Chicago, IL).
HE4 levels were determined using HE4 Fujirebio Diag-
nostics EIA assay. This solid-phase non-competitive im-
munoassay based on the direct sandwich technique was
carried out according to the manufacturer’s instructions.
The limit of detection was determined as < 2.5 pmol/l.
YKL40 levels were measured in serum using YKL40
ELISA kit from Metra Biosystems (Mountain View, CA).
Bcl-2 and Cathepsin L serum levels were measured
using human ELISA kit from Bender Med Systems
GmBH, Austria. These tests are for research use only.
The limit detection of human Bcl-2 was determined to
be < 0.5 ng/ml and for Cathepsin L 1.7 ng/ml.Range (7.38-21442) (49.22-22982)
HE4 [pmol/l]
Mean 78.87 602.45












Median 19.63 19.34 p = 0.5741
Range (17.52-24.19) (4.88-81.02)Statistic analysis
The average values of HE4, CA125, YKL-40, bcl-2 and
cathepsin-L were compared between the group of pa-
tients who underwent primary surgery and the group of
patients selected as eligible for neoadjuvant chemother-
apy and between groups of women that were created ac-
cording to the response to the first-line treatment. The
statistical analysis was performed using STATISTICA
9.1 PL and PQStat 1.4.6. programs. The average values
in each group were compared using nonparametric
Mann–Whitney U test and Kruskal-Wallis test. Receiver
operating characteristic (ROC) curves were obtained,
and the area under curve (AUC) was calculated with
95% confidence interval according to the nonparametric
method of DeLong [17]. We used also this method to
compare AUCs. The sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value (NPV)
were determined using cut-off value calculated usingYouden and deLong method. The level of significance
was taken as p < 0.05.
Results
When comparing the mean values of the concentrations
of selected tumor markers (CA125, HE4, YKL-40),
cathepsin-L and bcl-2 we found that statistically signifi-
cant differences between a group of women undergoing
primary surgical treatment and the patients qualified as
eligible for the neoadjuvant chemotherapy were applicable
only to the tumor markers (CA125 1206.79 vs 2432.38,
p = 0.000191; HE4 78.87 vs 602.45, p = 0.000004; YKL-40
108.13 vs 203.96, p = 0.003991). Average values of
cathepsin-L and Bcl-2 were similar in both groups and
statistically insignificant (Table 2). By limiting the study
group only to serous ovarian cancers we received very
similar results (Table 3). Comparison of average concen-
trations of proteins studied by us, depending on the re-
sponse to the first-line chemotherapy, are shown in
Table 4. We found statistically significant differences in
the mean concentrations of the tumour markers CA 125
and HE4 between the group of patients sensitive and re-
sistant to the first-line chemotherapy, and these values
were as follows, respectively (CA 125 575.77 vs 1338.79,
p = 0.038, HE4 254.42 vs 566.22, p = 0.045). In the case of
the average values of YKL-40 a statistically significant
Table 3 Preoperative markers, bcl-2 and cathepsin–L serum

























Median 20.98 20.07 p = 0.6913
Range (11.27-45.53) (4.88-81.02)
Chudecka-Głaz et al. Journal of Ovarian Research 2014, 7:62 Page 4 of 12
http://www.ovarianresearch.com/content/7/1/62difference was observed between the group of women sen-
sitive to platinum analogues and treatment refractory
(131.04 vs 231.02, p = 0.0218). We also made a compari-
son between a group of platinum sensitive patients with
platinum resistant and platinum refractory patients to-
gether (IS + R). In this comparison, the values of CA 125
and YKL-40 were significantly statistically higher in the
group of refractory and resistant cases as compared with
cases of ovarian cancer sensitive to chemotherapy based
on platinum (CA 125 1058.15 vs 575.77, p = 0.0324, YKL-
40 193.53 vs 131.04, p = 0.0339). There were no differ-
ences found in serum concentrations of cathepsin-L and
Bcl-2 in the compared groups. By limiting the study group
only to serous ovarian cancers it was found that only in
the case of CA 125 the average values are higher in a
group of women with resistant ovarian cancer as well as
resistant and refractory jointly, as compared with the can-
cer sensitive to the first-line treatment, and these values
were as follows, respectively: 1338.78 vs 656.25, p = .0258
and 1171 vs 656.25, p = 0.0451. In the case of HE4, YKL-
40, cathepsin-L and bcl-2 the differences were not statisti-
cally significant. At Figures 1, 2, 3 there is a graphic
presentation of the scatter of the values of the studied
tumour markers, depending on the treatment applied and
depending on the response to the first-line chemotherapy.The differences in the median values for HE4, CA 125 and
YKL-40 are clearly visible, which are greater in women
who start treatment with neoadjuvant chemotherapy as
compared with patients that primarily underwent radical
surgical procedures. Using the Youden method and the
DeLong method the cut-off values were determined for
the markers CA125, HE4 and YKL-40, which would iden-
tify the patients being the candidates for treatment with
neoadjuvant chemotherapy. The following cut off point
values were established: CA125-345 mIU/ml, HE4-218.43
pmol/ L and YKL-40-140.9 ng/ml. Based on these cut-off
points and the contingency table, the sensitivity, specifi-
city, positive and negative predictive values [PPV and
NPV] were calculated for the tested markers, which were
as follows: CA125 (83.3%; 75%; 80.6%; 78.3%), HE4 (86.6%;
91.3%; 92.9%; 84%) and YKL-40 (75%; 83.3%; 84%; 74.1%).
The Figures 4 and 5 show the ROC curves for CA
125, HE4 and YKL-40 as the markers preliminarily dis-
criminating patients with ovarian cancer into the cases
that are candidates for primary cytoreduction or not.
The AUC values, both within the entire group and in
the group of only serous carcinomas are the highest for
HE4 (0949 and 0941). When comparing values of the
area under the curve (AUC) for the tested markers, in
most cases no statistically significant differences were
found, besides the superiority of HE4 over YKL-40 in
the serous cancer group. For the whole study group:
AUC for HE4 (0.949) vs CA 125 (0.833), p = 0.073, HE4
(0.949) vs YKL-40 (0.821), p = 0.088, CA125 (0.833) vs
YKL-40 (0.821), p = 0.94. For the serous cancer group:
AUC for HE4 (0.949) vs CA 793 (0.833), p = 0.073, HE4
(0.949) vs YKL-40 (0.821), p = 0.088, CA125 (0.833) vs
YKL-40 (0.821), p = 0.94.
No cut-off points were determined in groups of pa-
tients analyzed in terms of sensitivity to platinum ana-
logues. The constructed ROC curves did not meet the
criteria of a valuable diagnostic test, as the areas under
the curve (AUC) for the CA 125, HE4 and YKL-40 were
in each case less than 0.5.
Discussion
In view of the rather numerous recent studies, it appears
that the neoadjuvant chemotherapy is a valuable option
for patients who cannot have the surgery with optimal
cytoreduction performed on them. A certain problem
could be the classification of patients into those being
eligible for an appropriate treatment option. In our
work, we made an initial attempt to assess the potential
usefulness of preoperative serum levels of commonly
known markers for predicting the optimal therapeutic
regimen: cytoreductive surgery followed by chemother-
apy or chemotherapy followed by cytoreductive surgery.
In addition, we assessed the relation of these markers
with response to the first-line chemotherapy.
Table 4 Preoperative markers, bcl-2 and cathepsin–L serum concentrations depending on response to chemotherapy
S IS p S R p IS R p S IS+R p
CA125 [IU/ml]
p = 0.038 p = 0.1852 p = 0.2261 p = 0.0324Median 575.77 1338.79 575.77 949.01 1338.79 949.01 575.77 1058.15
Range (7.38-2743.5) (464.43-4882.06) (7.38-2743.5) (49.23-22982) (464.43-4882.06) (49.23-22982) (7.38-2743.5) (49.23-22982)
HE4 [pmol/l]
p = 0.045 p = 0.268 p = 0.127 p = 0.0888Median 254.42 566.22 254.42 271.32 566.22 271.32 254.42 349.96
Range (2.5-1310.69) (106.96-1574.89) (2.5-1310.69) (2.5-590.13) (106.96-1574.89) (2.5-590.13) (2.5-1310.69) (2.5-1574.89)
YKL-40 [ng/ml]
p = 0.062 0 = 0.0218 p = 0.2452 p = 0.0339Median 131.04 143.55 131.04 231.02 143.55 231.02 131.04 193.53
Range (16.42-417.27) (55.06-235.01) (16.42-417.27) (63.98-437.01) (55.06-235.01) (63.98-437.01) (16.42-417.27) (55.06-437.01)
Cathepsin-L [ng/ml]
p = 0.3242 p = 0.1734 p = 0.2759 p = 0.3461Median 12.72 12.26 12.72 11.68 12.26 11.68 12.72 11.84
Range (8.42-46.45) (9.74-14.98) (8.42-46.45) (9.34-18.17) (9.74-14.98) (9.34-18.17) (8.42-46.45) (9.34-18.17)
bcl-2 [ng/ml]
p = 0.1010 p = 0.0719 p = 0.1073 p = 0.2777Median 24.37 32.48 24.37 16.73 32.48 16.73 24.37 20.84
Range (18.91-29.84) (9.89-81.02) (18.91-29.84) (4.88-30.94) (9.89-81.02) (4.88-30.94) (18.91-29.84) (4.88-81.02)


















Figure 1 Scatterplot of serum HE4 levels for women with ovarian
cancers according to primary treatment and platinum sensitivity.
Figure 2 Scatterplot of serum CA 125 levels for women with
ovarian cancers according to primary treatment and platinum
sensitivity.
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http://www.ovarianresearch.com/content/7/1/62CA125 is the most studied tumor marker for ovarian
cancer, known for its diagnostic and prognostic useful-
ness in malignant epithelial ovarian cancers. Many works
also report on the usefulness of this marker in the use of
the neoadjuvant chemotherapy on many levels [14,15,18]but there are also authors who question its relevance in
the said therapeutic process [19,20]. Of interest are stud-
ies carried out by Kang et al. [14], who studied 314
women with ovarian cancer and found that the CA 125
can be a very good predictor of selecting a suitable
Figure 3 Scatterplot of serum YKL-40 levels for women with
ovarian cancers according to primary treatment and platinum
sensitivity.
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ian cancer. The authors compared a group of patients
undergoing the primary cytoreductive surgery (n = 220)with patients treated with neoadjuvant chemotherapy
followed by secondary cytoreduction (n = 94). The initial
results of the comparison of both groups showed no dif-
ference in time to disease progression (PFS), but by ana-
lyzing a group treated with the neoadjuvant chemotherapy
and analyzing its various subgroups (age above/below
65 years, stage, histopathological type and level of CA
125) it turned out that it is just the marker level that is a
key factor. Patients having an baseline value of CA 125
above 2000 U/ml and qualified as eligible for the neoadju-
vant chemotherapy gain significant advantages in terms of
longer time to progression (HR 0.62, 95% CI 04 to 0.97,
p = 0.037). Gąsowska-Bodnar et al. [18] showed, however,
that the regression coefficient of CA 125 after two courses
of the neoadjuvant chemotherapy has statistically signifi-
cant effect on progression-free time (TTS- time to sur-
vival). Rocconi et al. [21] presented a study in which early
normalization of the CA 125 marker during chemother-
apy was associated with a greater sensitivity to platinum
analogues with a longer time to progression (PFS) and
overall survival time. The CA 125 as a strong predictor of
optimal cytoreduction was also described in studies con-
ducted by Vasudev et al. [22]. AUC in their research for
CA 125 as a predictor of optimal cytoreduction was 0756.
In our study we manifested the usefulness of CA 125 in
predicting the need of the neoadjuvant chemotherapy in a
selected group of patients with advanced ovarian cancer.
The area under the curve (AUC) for CA 125 was 0.833 for
the entire study group and 0.793 for the serous carcin-
omas group which is consistent with studies carried out
by Vasudev et al. [22]. We also showed a statistically sig-
nificant difference in baseline values of CA 125 among a
group of women undergoing the primary surgery followed
by the neoadjuvant chemotherapy and between the sensi-
tive and resistant patients to platinum analogues. Our
study confirmed the usefulness of CA 125, previously de-
scribed in the literature, in the neoadjuvant chemotherapy
prediction.
HE4 is a new tumour marker, recently approved for
the diagnosis and monitoring of ovarian cancer. Human
epididymis protein 4 (HE4) is a member of the “four-
disulfide core” family, heterogeneous group of small
acid- and heat-stable proteins of biological function not
yet detailed identified. A hypothesis was advanced that
the WFDC2 protein may be a component of the innate
immune response in the lung, nose and oral cavity
[23,24]. By immunohistochemical examination the ex-
pression of HE4 was found in a normal epithelium of
the genital tract in women, serous, endometrioid and
clear cell type neoplastic ovarian tumors [25]. Data on
the role of HE4 in the carcinogenesis are inconsistent.
Gao et al. [26] demonstrated that the transfer of “ex-
ogenous HE4 gene” to the ovarian cancer cell lines sig-
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Figure 4 ROC curves of HE4, CA 125 and YKL-40 at all tumours.
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http://www.ovarianresearch.com/content/7/1/62to the protective role of this gene in the ovarian cancer
progression process. Zou et al. [27] found out that the
HE4 gene silencing results in cell division stopping in
the G0/G1 phase which in turn is associated with the in-
hibition of proliferation, migration and invasion of theovarian cancer cells. The HE4 participation in promoting
the neoplastic tumor growth was also demonstrated by
other authors, they demonstrated that the HE4 expres-
sion in cancer cells is associated with greater adhesion,





















































































1-Specificity (false positive rate)
YKL-40, AUC=0.763
Figure 5 ROC curves of HE4, CA 125 and YKL-40 at serous type tumours.
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in the various diagnostic and prognostic aspects of the
ovarian cancer is still negligible. Only in recent years there
have been published a lot of works associated with this
marker [29-32]. Evaluation of usefulness of HE4 in pre-
dicting the success of cytoreductive surgery was analyzed
in four publications, and all these publications confirmedits usefulness [15,31-34] Kalapotharakos et al. [31] found a
significantly higher concentration of HE4 in a group of pa-
tients in which an attempt to perform cytoreductive sur-
gery (578 pmol/L) failed as compared with patients who
underwent radical surgery (278 pmol/L). In our study, the
mean value of HE4 in the group of patients radically ope-
rated at the moment of diagnosis was 78.87 pmol/L and
Chudecka-Głaz et al. Journal of Ovarian Research 2014, 7:62 Page 10 of 12
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602.45 pmol/L. Yang et al. [33] showed that the 600 pmol/L
is the cut-off value for HE4, above which a deferred cytore-
ductive surgery should be performed and the sensitivity
and specificity of the test were 77 and 32%, respectively. In
our study, the cut-off value for HE4 was lower and calcu-
lated based on the method of Youden was 218.43 pmol/L
achieving a sensitivity and specificity at 86.6 and 91.3%
levels, respectively. The cut-off value for HE4 (262 pmol/L)
approximate to ours was presented by Angioli et. al. [15].
The sensitivity and specificity of the test varied then
between 100 and 89.5% levels. They showed at the same
time that HE4 in comparison with CA 125 is a better
predictor of the feasibility of optimal cytoreduction, which
was also confirmed in our study. In studies conducted by
Braicu et al. [34] the 90% sensitivity was achieved in pre-
dicting incomplete cytoreduction if both markers CA 125
and HE4 had value exceeding 75 U/ml and 75 pmol/L. As-
suming for HE4 the cut-off value at 235 pmol/L and 500
pmol/L levels they reported sensitivity and specificity at
76.6 and 47.3 levels as well as 51.9% and 70.4%, respec-
tively. When they calculated the risk for incomplete cytore-
duction using both markers with cut-off values of 235
pmol/L for HE4 and 500 U/ml for CA 125, the sensitivity
was 64.8% and specificity 73.5%. The AUC for HE4 as a
predictor of suboptimal surgery in ovarian cancer was
0.634 (34). In our study, the area under the curve was
assessed for HE4 at 0.949 level for all the patients and
0.941 in the serous carcinomas group and these are the
results that show a high potential of the marker HE4 in
predicting the optimal cytoreduction which is consistent
with all previous studies by other authors [15,31-33]. So
far, no studies have been shown concerning the connec-
tion of HE4 with the platinum sensitivity in patients with
ovarian cancer. In our study, however we found a signifi-
cant difference in the values of HE4 in patient group
sensitive (254.42 pmol/L), and resistant to chemotherapy
(566.22 pmol/L), p = 0.045.
YKL-40 is a serum protein, whose elevated values
occur in the course of inflammatory and neoplastic dis-
eases. It was shown that the elevated values of YKL-40
in patients in the general population may be associated
with an increased risk of developing colorectal cancer
[35]. The immunoexpression in tissues is associated with
increased proliferation. High expression of YKL-40 in
conjunction with Ki-67 was showed in tissues of serous
low-differentiated ovarian cancer [36]. According to Yip
et al. [37] this marker is ranked on the 6th position of
the 175 tested compounds as potential markers for ova-
rian cancer. AUC for YKL-40 was 0.804, for CA 125
0.907 and for HE4 0.933. In our previous studies [38] we
showed that YKL-40 is elevated in the serum of patients
with ovarian cancer, however it did not demonstrate su-
periority over the CA 125. In the current study, wecompared the usefulness of YKL-40 in predicting opti-
mal cytoreduction. We found differences in serum con-
centrations in the compared groups, we carried out
analysis for the diagnostic test determining the ROC
curves and calculating the AUC, which was 0.821 for the
whole group and 0.763 for serous carcinomas. Despite
the high values of AUC, we did not demonstrate the su-
periority of YKL-40 over the CA 125 and especially over
the HE4. Serum levels of YKL-40 in our study were sig-
nificantly statistically higher in the group of women re-
fractory to platinum analogues as compared with
women sensitive to these drugs, which has not yet been
described in the relevant literature.
The apoptosis process plays an important role in the
carcinogenesis and is under the control of proteins from
bcl-2 family [39]. Numerous studies suggesting an asso-
ciation of bcl-2 with the course of ovarian cancer were
presented [39]. The relationship of the bcl-2 with the
ovarian cancer progression stage was shown [40], with
its usefulness in the early ovarian cancer detection [41]
as well as the prognosis of the disease course [42,43].
Research conducted by Crasta et al. [44] showed that the
factor associated with suboptimal cytoreduction is the
degree of angiogenesis intensification and at the same
time a negative correlation between bcl-2 and VEGF was
demonstrated. Dutta et al. [45] reported that chemother-
apy leads to increased apoptosis by independent p-53
way, causing a reduction of bcl-2 protein and survivin
but not bcl-XL. It was further found that applying 6
courses is more effective in the neoadjuvant chemother-
apy than 3 courses in terms of induction of apoptosis
[45]. In other reports it was shown that high expression
of bcl-2 has an adverse effect on the occurrence of
complete remission, but only in the cancer group TP 53
negative [46]. In our studies, in contrast to studies con-
ducted by Camlica et al. [47], we did not show any dif-
ferences in preoperative serum values of bcl-2 in both
tested groups, both in terms of optimal cytoreduction
and sensitivity to platinum analogues. It does not appear
that serum levels of bcl-2 may have the prognostic sig-
nificance in this regard.
Cathepsin-L is a lysosomal endopeptidase belonging to
the cysteine protease papain superfamily. It is synthe-
sized as a proenzyme, then modified and after transport
to lysosomes it performs many functions in the organ-
ism [48,49]. Physiologically it is involved in proteolysis
and release of thyroxine and triodotironin, in the thyroid
gland, it is involved in the immunological response by
activating a number of processes that result in the for-
mation of the MHC II molecules and consequently in
antigen presentation. It also plays a role in the process
of spermatogenesis as well as oogenesis and embryo-
genesis [48]. The share of cathepsin-L in pathological pro-
cesses such as the neoplastic process is also postulated. It is
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of hydrolyzing components of the extracellular matrix
allowing tumour cells both local invasion and distant
metastasis [48]. Cathepsin elevated levels were observed in
serum of patients with ovarian cancer [49-52]. Nishida
et al. [49] demonstrated that elevated cathepsin-L levels,
especially while determining CA 125 and CA 72–4, can be
a helpful method of detection of early ovarian cancer.
Research conducted by Zhang et al. [50] showed that
cathepsin-L, jointly with heparanase and matrix
metalloproteinase-9 correlate with malignant invasion and
progression in ovarian cancer and their combined deter-
mination can be a good predictor of the presence of metas-
tases prior to the planned surgery. Similar results were
presented by Kolwijck et al. [53], as well as by Wang et al.
[52]. The values of cathepsin L obtained in the research
conducted by Zhang et al. [50] are as follows: the mean
value in patients with ovarian cancer 21.23 ng/ml, in
healthy patients 5.59 ng/ml, in advanced ovarian cancer
22.6 ng/ml and at the FIGO stage I-II 19.6 ng/ml. The
AUC value was 0.708 for cathepsin L and 0.776 for CA
125. In our study there was no difference in the values of
cathepsin-L between the study groups. However, in each
tested group the cathepsin-L values were higher than ex-
pected in healthy patients group (according to manufac-
turer the average expected values are about 5 ng/ml). The
same value of cathepsin-L were observed preoperatively in
patients initially treated with surgery vs. initially treated
with chemotherapy as well as the same values regardless of
the response to chemotherapy suggest that cathepsin-L
cannot be probably a good predictor of patient eligibility
for appropriate treatment groups.
After detailed analysis of the tested material, and in
summing the results it appears that the most promising
marker can be the HE4 marker both in forecasting the
optimal cytoreduction in the primary surgical treatment
of ovarian cancer as well as for predicting response to
chemotherapy based on platinum analogues. Further
prospective studies on an exhaustive material are abso-
lutely needed to confirm the results of the authors and
of the cited research.
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